Trial Information
Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (IHCIS)
Inclusion Criteria:
- Evidence of two or more medical encounters with a diagnosis of kidney cancer
(ICD-9-CM 189.0) or malignant neoplasm of the renal pelvis (189.1), and
- Two or more medical encounters with a diagnosis of distant secondary malignant
neoplasm (ICD-9-CM 197.XX-199.0, excluding 198.0 [kidney metastasis]) on different
days <120 days apart (the date of the earliest such encounter will be designated the
"index date").
Exclusion Criteria:
- evidence of receipt of chemotherapeutic agents indicated or used in the treatment of
advanced TCC, or
- Evidence of cystoscopy, biopsy of the bladder, or radical cystectomy
- Subjects with evidence of any other primary cancer
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Retrospective
Outcome Measure:
New and existing claims of metastatic renal cell carcinoma across multiple years
Outcome Description:
Identifying new and existing claims (based on claims based case-ascertainment algorithm) of metastatic renal cell carcinoma across multiple years in IHCIS database
Outcome Time Frame:
2000 -2009 (up to 10 years)
Safety Issue:
No
Principal Investigator
GSK Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
GlaxoSmithKline
Authority:
United States: No Health Authority
Study ID:
114867
NCT ID:
NCT01381614
Start Date:
March 2011
Completion Date:
December 2011
Related Keywords:
- Carcinoma, Renal Cell
- retrospective database analysis
- economic burden
- Carcinoma
- Carcinoma, Renal Cell